NasdaqGM - Nasdaq Real Time Price USD
Kalaris Therapeutics, Inc. (KLRS)
2.7450
-0.0850
(-3.00%)
As of 10:01:29 AM EDT. Market Open.
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Andrew Oxtoby | President, CEO & Director | -- | -- | 1974 |
| Dr. Srinivas Akkaraju M.D., Ph.D. | Director & Co-Founder | -- | -- | 1968 |
| Dr. Michael Philip Dybbs Ph.D. | Director & Co-Founder | -- | -- | 1975 |
| Dr. Napoleone Ferrara M.D. | Director & Co-Founder | -- | -- | 1957 |
| Dr. Samir C. Patel M.D. | Director & Co-Founder | -- | -- | 1961 |
| Mr. Brett R. Hagen | Principal Financial Officer & Principal Accounting Officer | -- | -- | 1973 |
| Dr. Jeffrey Nau MMS, Ph.D. | Chief Operating Officer | -- | -- | 1976 |
| Dr. Matthew Feinsod M.D. | Chief Medical Officer | -- | -- | 1971 |
Kalaris Therapeutics, Inc.
628 Middlefield Road
Palo Alto, CA 94301
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14
Description
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
Corporate Governance
Kalaris Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
August 7, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC
Kalaris Therapeutics, Inc. Earnings Date
Recent Events
Related Tickers
SER Serina Therapeutics, Inc.
6.00
+1.91%
LIMN Liminatus Pharma, Inc.
5.48
-4.63%
KLTO Klotho Neurosciences, Inc.
0.1804
-4.55%
ICCC ImmuCell Corporation
6.26
+1.31%
ZURA Zura Bio Limited
1.0449
+0.47%
APLM Apollomics, Inc.
7.39
-0.54%
4565.T Nxera Pharma Co., Ltd.
818.00
+1.74%
SABS SAB Biotherapeutics, Inc.
1.7300
-6.99%
HOOK HOOKIPA Pharma Inc.
1.4976
-7.56%
CTNM Contineum Therapeutics, Inc.
3.7300
-4.60%